Drug Profile

Research programme: oncology therapeutics - Neovia Oncology

Alternative Names: Neo 2; Neo 3; Neo 4; Neo AD1; NEV 2; NEV 3; NEV 4; NEV AD1

Latest Information Update: 04 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neovia Oncology
Class Antineoplastics; Camptothecins; Colchicum alkaloids; Small molecules
Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

24 Aug 2023 oncology therapeutics are still in preclinical development for Cancer in USA.
31 May 2015 Preclinical trials in Cancer in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com